Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. Issue 2 (10th July 2019)

• Record Type: Journal Article
• Authors: Hoda, Raza S; Brogi, Edi; Pareja, Fresia; Nanjangud, Gouri; Murray, Melissa P; Weigelt, Britta; Reis‐Filho, Jorge S; Wen, Hannah Y
• Is Part Of: Histopathology. Volume 75:Issue 2(2019)
• Page Start: 213
• Page End: 224
• Publication Date: 2019-07-10
• Subjects: breast -- basal‐like carcinoma -- ETV6‐NTRK3 -- secretory breast carcinoma -- targeted therapy -- translocation; Histology, Pathological -- Periodicals; 611.018
• DOI: 10.1111/his.13879
• Languages: English
• ISSNs: 0309-0167

Abstract

Abstract : Aims: Secretory carcinoma of the breast (SCB) is a rare histological type of breast carcinoma with a generally indolent clinical behaviour. We aim to elucidate the clinical, pathological and molecular findings of SCB cases and identify characteristics associated with aggressive clinical courses. Methods and results: Fourteen patients with SCB were identified, including 12 women and two men, with a median age of 56 years (range = 8–81 years). Clinical data, histological diagnosis, molecular findings and follow‐up were reviewed. Eight patients presented with palpable masses and four patients with radiographic abnormalities. All cases were unilateral. Surgical procedures included excisional biopsies and ipsilateral mastectomies. In 10 cases, oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) results were obtained, with six cases positive for ER and three positive for PR. All cases lacked HER2 overexpression. Sentinel lymph node biopsy was performed in 10 cases, and two patients had axillary lymph node metastasis. Follow‐up ranged from 21 to 212 months (median = 70 months). Two patients developed distant metastasis of SCB. Molecular analysis of these aggressive tumours revealed amplification of the 16p13.3 locus, a TERT promotor mutation and loss of 9p21.3 locus. Review of the literature for SCB cases with distant metastasis was performed. Conclusions: Although SCBs are generally associated with a favourable prognosis, our study and review demonstrate that a subset of SCBs may develop distant metastases. Further studies are warranted to identify markers predictive of more aggressive clinical behaviour in this rare breast cancer subtype.